AMSTERDAM Mon Feb 24, 2014 1:09am EST
AMSTERDAM Feb 24 (Reuters) - Pharming Group NV : * FDA extends prescription drug user fee act date for co's biologics license
application for drug Ruconest * FDA extends date to July 16, 2014 * Cos U.S. marketing approval of Ruconest that treats acute angioedema attacks in patients with hereditary angioedema
AMSTERDAM Feb 24 (Reuters) - Pharming Group NV : * FDA extends prescription drug user fee act date for co's biologics license
application for drug Ruconest * FDA extends date to July 16, 2014 * Cos U.S. marketing approval of Ruconest that treats acute angioedema attacks in patients with hereditary angioedema
via Smart Health Shop Forum http://ift.tt/1doHZzw
No comments:
Post a Comment